Multimodal profiling of adults hospitalized with acute heart failure and cardiogenic shock
Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE
This project will test whether combining routine hospital data with extra blood and urine samples can help doctors identify types of cardiogenic shock and predict 30-day outcomes in adults hospitalized with acute heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Heart Center Freiburg - Bad Krozingen Academic / other |
| Locations | 4 sites (Bad Krozingen and 3 other locations) |
| Trial ID | NCT07515508 on ClinicalTrials.gov |
What this trial studies
This observational project collects clinical findings, imaging results, and biomarkers—including sex-specific factors—together with additional blood and urine samples for biobanking from adults hospitalized with acute heart failure and SCAI stage B–E cardiogenic shock. No experimental treatments are given; researchers will use routinely collected care data plus the stored samples to define phenotypes and search for associations with 30‑day mortality and other outcomes. Participants will be followed after hospital discharge to capture short‑term outcomes. The aim is to improve risk stratification and understanding of distinct cardiogenic shock presentations.
Who should consider this trial
Good fit: Adults hospitalized with acute heart failure who meet SCAI stage B–E cardiogenic shock criteria and can provide informed consent (excluding post‑cardiothoracic surgery shock) are ideal candidates.
Not a fit: Patients unable to give informed consent for reasons unrelated to cardiogenic shock or those with cardiogenic shock following cardiothoracic surgery are excluded and unlikely to benefit directly from participation.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify high-risk patients earlier and tailor care to reduce short-term deaths and complications.
How similar studies have performed: Previous observational cohorts have linked biomarkers and clinical phenotypes to outcomes in cardiogenic shock, but combining routine care data with multimodal, sex‑specific biomarker profiling remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients hospitalized with acute heart failure SCAI stage B - E. Exclusion Criteria: * Not capable of providing informed consent due to reasons not attributable to cardiogenic shock * Cardiogenic shock following cardiothoracic surgery
Where this trial is running
Bad Krozingen and 3 other locations
- University Heart Center Freiburg - Bad Krozingen — Bad Krozingen, Germany (Recruiting)
- University Medical Center Freiburg, Interdisciplinary Medical Intensive Care — Freiburg im Breisgau, Germany (Recruiting)
- Department for Internal Medicine 8, Clinic for Cardiology and Rhythmology, University Clinic of the Paracelsus Medi-cal University Nuremberg — Nuremberg, Germany (Active_not_recruiting)
- Schwarzwald Baar Klinikum Villingen-Schwenningen, Klinik für Kardiologie und Intensivmedizin — Villingen-Schwenningen, Germany (Recruiting)
Study contacts
- Study coordinator: Lucas Bacmeister, MD
- Email: lucas.bacmeister@uniklinik-freiburg.de
- Phone: 004976127034010
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.